ArticleAging2020
Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 69 citations in OpenAlex.
- RNA NPlant cell reports · 2026Review
- METTL14-Mediated lncRNA MSTRG.292666.16 mInternational journal of molecular sciences · 2026Article
- METTL3 and METTL14 drive pancreatic adenocarcinoma progression via m6A-dependent alternative splicing in PANC-1 cells.Discover oncology · 2025Article
- Role, mechanism, and application of N6-methyladenosine in hepatobiliary carcinoma.World journal of gastrointestinal oncology · 2025Review
- METTL14 suppresses the migration and invasion of hepatocellular carcinoma cells by m6A methylation of RPLP2.Scientific reports · 2025Article
- METTL protein family: focusing on the occurrence, progression and treatment of cancer.Biomarker research · 2024Review
- METTL14 contributes to the progression of nasopharyngeal carcinoma through regulating the stability of AOC1 mRNA.Hereditas · 2024Article
- New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma.Acta pharmacologica Sinica · 2024Review
- Ribosome profiling: a powerful tool in oncological research.Biomarker research · 2024Review
- RNA m6A methylation regulators in liver cancer.Cancer cell international · 2024Review
- The role of RNA modifications in hepatocellular carcinoma: functional mechanism and potential applications.Frontiers in immunology · 2024Review
- Compression Promotes the Osteogenic Differentiation of Human Periodontal Ligament Stem Cells by Regulating METTL14-mediated IGF1.Current stem cell research & therapy · 2024Article
- Non-coding RNA methylation modifications in hepatocellular carcinoma: interactions and potential implications.Cell communication and signaling : CCS · 2023Review
- The m6A reader YTHDC1-mediated lncRNA CTBP1-AS2 m6A modification accelerates cholangiocarcinoma progression.Heliyon · 2023Article
- METTL14‑mediated RNA methylation in digestive system tumors.International journal of molecular medicine · 2023Review
- Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.BMC medical genomics · 2023Article
- Advances in targeting RNA modifications for anticancer therapy.Trends in cancer · 2023Review
- Dynamic m6A-ncRNAs association and their impact on cancer pathogenesis, immune regulation and therapeutic response.Genes & diseases · 2023Review
- Epigenetic targeting of autophagy for cancer: DNA and RNA methylation.Frontiers in oncology · 2023Review
- Recent Advances in RNA mCancer treatment and research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m6A) RNA methylation is the most prevalent modification of messenger RNAs (mRNAs) and catalyzed by a multicomponent methyltransferase complex (MTC), among which methyltransferase-like 3 (METTL3) and METTL14 are two core molecules. However, METTL3 and METTL14 play opposite regulatory roles in hepatocellular carcinoma (HCC). Based on The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) database, we conducted a multi-omics analysis of METTL3 and METTL14 in HCC, including RNA-sequencing, m6ARIP-sequencing, and ribosome-sequencing profiles. We found that the expression and prognostic value of METTL3 and METTL14 are opposite in HCC. Besides, after METTL3 and METTL14 knockdown, most of the dysregulated mRNAs, signaling pathways and biological processes are distinct in HCC, which partly explains the contrary regulatory role of METTL3 and METTL14. Intriguingly, these mRNAs whose stability or translation efficiency are influenced by METTL3 or METTL14 in an m6A dependent manner, jointly regulate multiple signaling pathways and biological processes, which supports the cooperative role of METTL3 and METTL14 in catalyzing m6A modification. In conclusion, our study further clarified the contradictory role of METTL3 and METTL14 in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.